Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INC102
- Development stage
- Preclinical
- Lead developer
- Liminatus Pharma
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
INC102 is an early-stage, armored chimeric antigen receptor T-cell (CAR-T) therapy candidate developed by InnocsAI. It is designed to target solid tumors expressing mesothelin and CD276 (B7-H3). As a follow-on construct to IBC101, INC102 incorporates a dominant-negative TGF-β receptor (dnTGFβR) strategy. This armoring is intended to shield the CAR-T cells from the immunosuppressive effects of TGF-β within the tumor microenvironment, thereby enhancing T-cell persistence and anti-tumor activity. The therapy is being positioned for biomarker-selected solid tumor indications.
02
Targets
B7-H3TGFBR (TGF-beta receptor)Mesothelin
Beyond the preview
Go deeper on INC102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INC102.